![]() |
![]() | ![]() |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Commonwealth Biotechnologies CBTE may be the last of the undiscovered biotechs working in the fields of genomics and dna sequencing. While other small companies have seen their market caps explode (HYSQ $800M, CRGN $2.7B, GLGC $1.9B etc) as excitment over different gene sciences grow-CBTE is trading near 12 with a tiny market cap of $20M In additon to dna sequencing cbi-biotech.com and genomic sequencing cbi-biotech.com CBTE is also involved in genetic testing services including human genetic analysis and DNA fingerprinting cbi-biotech.com and protein sequencing cbi-biotech.com CBTE also does Gene Synthesis-the application of sophisticated technologies to construct completely synthetic “designer genes” expressing the exact desired protein cbi-biotech.com and DNA/RNA sequencing cbi-biotech.com CBTE also offers its proprietary AccuTrac for DNA Sequencing cbi-biotech.com Hoovers rates CBTE's closest competitors to be Hyseq,Genset and Qiagen hoovers.com CBTE float 1.2M, extremely thin, starting to edge up- currently trading near 12 -market cap roughly $20M | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |